



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/903,023	07/11/2001	Jack R. Wands	21486-032DIV1

MINTZ, LEVIN, COHN, FERRIS,  
 GLOVSKY and POPEO, P.C.  
 One Financial Center  
 Boston, MA 02111

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

## CONFIRMATION NO. 3871

## FORMALITIES LETTER



\*OC00000006501741\*

Date Mailed: 08/31/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

- Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Express Mail Label No.: EL862265645US  
Date of Deposit: October 11, 2001

10-12-01

OIPE

GA41642

Attorney Docket No. 21486-032DIV1

BCK Seq



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*  
SERIAL NUMBER: 09/903,023 EXAMINER: Not Yet Assigned  
FILING DATE: July 11, 2001 ART UNIT: 1642  
FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

RECEIVED

October 11, 2001  
Boston, Massachusetts

OCT 17 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the above-identified application are the following documents:

- Response to Notice to Comply (1 pg.);
- Preliminary Amendment (2 pgs.);
- Sequence Listing (15 pgs.);
- One Diskette;
- Statement in Support of Computer Readable Form Submission (1 pg.);
- Copy of Notice to Comply (2 pgs.); and
- Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at 617-542-6000, Boston, Massachusetts.

APPLICANTS: Wands, et al.  
U.S.S.N.: 09/903,023


Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 21486-032DIV1). A duplicate copy of this Petition is enclosed.

Respectfully submitted,

October 11, 2001

*IAB*  
Ingrid A. Beattie  
Ingrid A. Beattie, Reg. No. 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 1575124v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*

SERIAL NUMBER: 09/903,023

EXAMINER: Not Yet Assigned

FILING DATE: July 11, 2001

ART UNIT: 1642

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

RECEIVED

October 11, 2001  
Boston, Massachusetts

OCT 17 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES

in response to the notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, mailed August 31, 2001, in the above-identified application, Applicants submit a substitute paper copy, and a computer readable form of the Sequence Listing. Also enclosed are a Preliminary Amendment, *seq. listing*, a Statement in Support of Computer Readable Form Submission, and a copy of the Notice to File Corrected Application Papers. Please charge any additional fees that may be due, or credit any overpayment to Deposit Account No. 50-0311, Reference No. 21486-032DIV1.

Respectfully submitted,

*Ingrid A. Beattie*

Ingrid A. Beattie, Reg. No. 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241